KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Assets: 2020-2025

Historic Non-Current Assets for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $685.4 million.

  • Recursion Pharmaceuticals' Non-Current Assets rose 171.64% to $685.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $685.4 million, marking a year-over-year increase of 171.64%. This contributed to the annual value of $734.3 million for FY2024, which is 240.66% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Non-Current Assets of $685.4 million as of Q3 2025, which was down 4.16% from $715.2 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Non-Current Assets' 5-year high stood at $734.3 million during Q4 2024, with a 5-year trough of $50.1 million in Q1 2021.
  • For the 3-year period, Recursion Pharmaceuticals' Non-Current Assets averaged around $398.4 million, with its median value being $252.3 million (2024).
  • Data for Recursion Pharmaceuticals' Non-Current Assets shows a peak YoY soared of 240.66% (in 2024) over the last 5 years.
  • Over the past 5 years, Recursion Pharmaceuticals' Non-Current Assets (Quarterly) stood at $75.6 million in 2021, then surged by 73.85% to $131.5 million in 2022, then soared by 63.96% to $215.6 million in 2023, then surged by 240.66% to $734.3 million in 2024, then surged by 171.64% to $685.4 million in 2025.
  • Its last three reported values are $685.4 million in Q3 2025, $715.2 million for Q2 2025, and $721.1 million during Q1 2025.